BioBlog

Forty four states filed against a group of 20 drug makers this week include Teva Pharmaceuticals, Inc., claiming price fixing, collusions and more. Meanwhile, another report uncovered that hospitals often charge double and sometimes even triple to private insurers over what Medicare would pay for

This week’s Innovation Partners BioBlog looks at top stories from the world of pharmaceutical and healthcare news. Elderly people who survive the three most common types of cancer are at an increase for brain metastasis, according to a new report. The Trump Administration continues to push for the

Discussions in the news this week circle around CAR-T payments, PBM rebates, and whether or not the Trump Administration will continue voluntary payment models. A new blockchain healthcare initiative demonstrates how the Internet of Things (IoT), blockchain, and healthcare can work together for

Is it time to give up on biosims as the answer to high drug prices? Some experts say yes with suggestions for greater savings. Other measures this week to lower healthcare costs include CMS allowing health insurers to implement copay accumulator programs, which are intended to encourage the use of

Activity at the state and federal level this week is heating up in the fight against higher drug and healthcare costs. PBMs testified before federal lawmakers, who seemed uncertain of their role in the industry. The Montana Senate delayed the Medicaid bill, and Pennsylvania’s Attorney General filed

What should insurers consider when they revise their formularies? Is fee-for-service the answer to the future of healthcare? We look into these top stories and more in this week’s Innovation Partners BioBlog. Other stories this week include the expansion of the Muriad-AstraZeneca/Merck partnership,

This week’s Innovation Partners BioBlog comes to you a day later than our usual publication date and includes highlights of the AACR conference as well as an announcement from Memorial Sloan Kettering on a new study showing CAR T cell therapy results in metastatic lung and breast cancer as well as

Debates continue in the government’s quest to push down the cost of prescription drugs as two new treatments, one for postpartum depression and another for depression hit the market with high price tags. Others are tackling “surprise” medical bills, but the ramifications are problematic. These